Aerie Pharmaceuticals Inc. priced and upsized a previously announced offering by $25 million to $75 million.

Each share issued under the offering will be sold at $53.75 apiece, with the issue to be closed by June 1.

Aerie Pharmaceuticals sold a further $50 million via an at-the-market program via Cantor Fitzgerald & Co. that is expected to close by May 31.

Aerie plans to use the net proceeds from the offerings for general corporate purposes, including the commercialization and clinical efforts for its products Rhopressa and Roclatan.

Cantor Fitzgerald & Co. is the sole book runner for both transactions.